Clinical efficacy and safety of erlotinib combined with chemotherapy in the treatment of advanced pancreatic cancer:A meta-analysis

作     者：Xiao-Yan Liu Hong-Nian Pan Yue Yu 

作者机构：Cheeloo College of MedicineShandong UniversityJinan 250012Shandong ProvinceChina Department of GastroenterologyThe First Affiliated Hospital of USTCDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001Anhui ProvinceChina Department of GastroenterologyThe Lu’an Hospital Affiliated to Anhui Medical UniversityThe Lu’an People's HospitalLu’an 237000Anhui ProvinceChina 

出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第3期

页      面：921-931页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by National Natural Science Foundation of China,No.31870993 Fundamental Research Funds for the Central Universities,No.WK9110000005 Anhui Provincial Health Research Project,No.AHWJ2022c020 Anhui Medical University Campus Level Research Fund,No.2020xkj229 Lu'an City Science and Technology Plan Project,No.2022Lakj009 New Technology and Project of Lu'an People's Hospital,No.2021xjs10 

主　　题：Erlotinib Chemotherapy Advanced pancreatic cancer Efficacy Safety Meta-analysis 

摘      要：BACKGROUND Advanced pancreatic cancer is resistant to chemotherapeutic drugs,resulting in limited treatment efficacy and poor *** administration of the chemotherapeutic gemcitabine and erlotinib is considered a potential first-line treatment for advanced pancreatic ***,their comparative benefits and potential risks remain *** To assess the clinical efficacy and safety of erlotinib combined with other chemotherapy regimens for the treatment of advanced pancreatic *** Literature on the clinical efficacy and safety of erlotinib combined with chemotherapy for advanced pancreatic cancer was retrieved through an online *** retrieved literature was subjected to a methodological qualitative assessment and was analyzed using the RevMan 5.3 *** randomized controlled trials involving 2444 patients with advanced pancreatic cancer were included in the *** Compared with chemotherapeutic treatment,erlotinib combined with chemotherapy significantly prolonged the progression-free survival time of pancreatic cancer patients[hazard ratio(HR)=0.78,95%CI:0.66-0.92,P=0.003].Meanwhile,the overall survival(HR=0.99,95%CI:0.72-1.37,and P=0.95)and disease control rate(OR=0.93,95%CI:0.45-0.91,P=0.84)were not significantly *** terms of safety,the erlotinib and chemotherapy combination was associated with a significantly higher risk of diarrhea(OR=3.59,95%CI:1.63-7.90,P0.05)and rash(OR=3.63,95%CI:1.64-8.01,P0.05)compared with single-agent ***,the risk of vomiting(OR=1.27,95%CI:0.62-2.59,P=0.51),regurgitation/anorexia(OR=1.61,95%CI:0.25-10.31,P=0.62),and infection(OR=0.72,95%CI:0.28-1.87,P=0.50)were not significant in either *** Compared with a single chemotherapeutic modality,erlotinib combined with gemcitabine can prolong progression-free survival in pancreatic cancer,but does not improve survival benefit or disease control rate,and can increase the risk of diarrhea and rash.